C4 Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
18/02/2025 14:21
* C4 Therapeutics Inc CCCC.OQ CCCC.O is expected to show
a
rise in quarterly revenue when it reports results on February
20 (estimated) for the period ending December 31 2024
* The Watertown Massachusetts-based company is expected to
report
a 57.2% increase in revenue to $5.125 million from $3.26 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for C4 Therapeutics Inc is
for a
loss of 48 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for C4
Therapeutics
Inc is $13.00, above its last closing price of $3.18.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 -0.36 -0.38 -0.35 Beat 7.9
Jun. 30 2024 -0.37 -0.37 -0.26 Beat 30
Mar. 31 2024 -0.36 -0.35 -0.41 Missed -16.7
Dec. 31 2023 -0.64 -0.68 -0.70 Missed -2.6
Sep. -0.67 -0.66 -0.52 Beat 21.2
30 2023
Jun. 30 2023 -0.69 -0.69 -0.73 Missed -6.1
Mar. 31 2023 -0.73 -0.75 -0.71 Beat 4.8
Dec. 31 2022 -0.73 -0.74 -0.77 Missed -3.5
This summary was machine generated February 18 at 14:21 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)